nach oben

Journal of Neurology

Erschienen in:

29.01.2019 | Review

Magnetic resonance imaging in immune-mediated myelopathies

verfasst von: M. J. Wendebourg, S. Nagy, T. Derfuss, K. Parmar, R. Schlaeger

Erschienen in: Journal of Neurology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Immune-mediated myelopathies are a heterogeneous group of inflammatory spinal cord disorders including autoimmune disorders with known antibodies, e.g. aquaporin-4 IgG channelopathy or anti-myelin oligodendrocyte glycoprotein-associated myelitis, myelopathies in the context of multiple sclerosis and systemic autoimmune disorders with myelopathy, as well as post-infectious and paraneoplastic myelopathies. Although magnetic resonance imaging of the spinal cord is still challenging due to the small dimension of the cord cross-section and frequent movement and susceptibility artifacts, recent methodological advances have led to improved diagnostic evaluation and characterization of immune-mediated myelopathies. Topography, length and width of the lesion, gadolinium enhancement pattern, and changes in morphology over time help in narrowing the broad differential diagnosis. In this review, we give an overview of recent advances in magnetic resonance imaging of immune-mediated myelopathies and its role in the differential diagnosis and monitoring of this heterogeneous group of disorders.

Stroman PW, Wheeler-Kingshott C, Bacon M et al (2014) The current state-of-the-art of spinal cord imaging: methods. Neuroimage 84:1070–1081PubMedCrossRef

Rovira À, Wattjes MP, Tintoré M et al (2015) MAGNIMS study group. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol 11:471–482PubMedCrossRef

Wattjes MP, Harzheim M, Kuhl CK et al (2006) Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic mr imaging criteria for multiple sclerosis? AJNR Am J Neuroradiol 27:1794–1798PubMedPubMedCentral

Stankiewicz JM, Neema M, Alsop DC et al (2009) Spinal cord lesions and clinical status in multiple sclerosis: a 1.5 T and 3 T MRI study. J Neurol Sci 279:99–105PubMedPubMedCentralCrossRef

Valsasina P, Aboulwafa M, Preziosa P et al (2018) Cervical cord T1-weighted hypointense lesions at MR imaging in multiple sclerosis: relationship to cord atrophy and disability. Radiology 288:234–244PubMedCrossRef

Bot JC, Barkhof F (2009) Spinal-cord MRI in multiple sclerosis: conventional and nonconventional MR techniques. Neuroimaging Clin N Am 19:81–99PubMedCrossRef

Bot JC, Barkhof F, Polman CH et al (2004) Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 62:226–233PubMedCrossRef

Weier K, Mazraeh J, Naegelin Y et al (2012) Biplanar MRI for the assessment of the spinal cord in multiple sclerosis. Mult Scler 18:1560–1569PubMedCrossRef

Filippi M, Rocca MA, Ciccarelli O et al (2016) MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 15:292–303PubMedPubMedCentralCrossRef

10.

Tartaglino LM, Friedman DP, Flanders AE et al (1995) Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology 195:725–732PubMedCrossRef

11.

Kearney H, Altmann DR, Samson RS et al (2015) Cervical cord lesion load is associated with disability independently from atrophy in MS. Neurology 84:367–373PubMedCrossRef

12.

Kearney H, Miszkiel KA, Yiannakas MC et al (2016) Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis. Mult Scler 22:910–920PubMedCrossRef

13.

Thorpe JW, Kidd D, Moseley IF et al (1996) Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 46:373–378PubMedCrossRef

14.

Wattjes MP, Raab P (2017) Brain and spinal cord MRI in multiple sclerosis: an update. Neurol Int Open 1:e294–e306CrossRef

15.

Gass A, Filippi M, Rodegher ME et al (1998) Characteristics of chronic MS lesions in the cerebrum, brainstem, spinal cord, and optic nerve on T1-weighted MRI. Neurology 50:548–550PubMedCrossRef

16.

D’Amico E, Patti F, Leone C et al (2016) Negative prognostic impact of MRI spinal lesions in the early stages of relapsing-remitting multiple sclerosis. Mult Scler J Exp Transl Clin 9:2:2055217316631565

17.

Coret F, Bosca I, Landete L et al (2010) Early diffuse demyelinating lesion in the cervical spinal cord predicts a worse prognosis in relapsing-remitting multiple sclerosis. Mult Scler 16:935–941PubMedCrossRef

18.

Dekker I, Sombekke MH, Witte BI et al (2018) Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis. Mult Scler 24:481–490PubMedCrossRef

19.

Okuda DT, Mowry EM, Cree BA et al (2011) Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology 76:686–692PubMedPubMedCentralCrossRef

20.

Sombekke MH, Wattjes MP, Balk LJ et al (2013) Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. Neurology 80:69–75PubMedCrossRef

21.

Arrambide G, Rovira A, Sastre-Garriga J et al (2018) Spinal cord lesions: a modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. Mult Scler 24:301–312PubMedCrossRef

22.

Kearney H, Miller DH, Ciccarelli O (2015) Spinal cord MRI in multiple sclerosis—diagnostic, prognostic and clinical value. Nat Rev Neurol 11:327–338PubMedCrossRef

23.

Tsagkas C, Magon S, Gaetano L et al (2018) Spinal cord volume loss: a marker of disease progression in multiple sclerosis. Neurology 91:e349–e358PubMedCrossRef

24.

Lukas C, Sombekke MH, Bellenberg B et al (2013) Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. Radiology 269:542–552PubMedCrossRef

25.

Aymerich FX, Auger C, Alonso J et al (2018) Cervical cord atrophy and long-term disease progression in patients with primary-progressive multiple sclerosis. AJNR Am J Neuroradiol 39:399–404PubMedCrossRefPubMedCentral

26.

Tsagkas C, Magon S, Gaetano L et al (2018) Preferential spinal cord volume loss in primary progressive multiple sclerosis. Mult Scler. https://doi.org/10.1177/1352458518775006 CrossRefPubMed

27.

Lukas C, Knol DL, Sombekke MH et al (2015) Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. J Neurol Neurosurg Psychiatry 86:410–418PubMedCrossRef

28.

Losseff NA, Webb SL, O’Riordan JI et al (1996) Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119:701–708PubMedCrossRef

29.

Pezold S, Amann M, Weier K et al (2014) A semi-automatic method for the quantification of spinal cord atrophy. In: Yao J, Klinder T, Li S (eds) Computational methods and clinical applications for spine imaging, Lecture notes in computational vision and biomechanics, vol 17. Springer, Cham. https://doi.org/10.1007/978-3-319-07269-2_13 CrossRef

30.

De Leener B, Taso M, Cohen-Adad J et al (2016) Segmentation of the human spinal cord. Magma 29:125–153PubMedCrossRef

31.

Amann M, Pezold S, Naegelin Y et al (2016) Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial). J Neurol 263:1364–1374PubMedCrossRef

32.

Papinutto N, Schlaeger R, Panara V et al (2015) 2D phase-sensitive inversion recovery imaging to measure in vivo spinal cord gray and white matter areas in clinically feasible acquisition times. J Magn Reson Imaging 42:698–708PubMedCrossRef

33.

Weigel M, Bieri O (2018) Spinal cord imaging using averaged magnetization inversion recovery acquisitions. Magn Reson Med 79:1870–1881PubMedCrossRef

34.

Schlaeger R, Papinutto N, Panara V et al (2014) Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol 76:568–580PubMedPubMedCentralCrossRef

35.

Schlaeger R, Papinutto N, Zhu AH et al (2015) Association between thoracic spinal cord gray matter atrophy and disability in multiple sclerosis. JAMA Neurol 72:897–904PubMedPubMedCentralCrossRef

36.

Laule C, Vavasour IM, Zhao Y et al (2010) Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis. Mult Scler 16:670–677PubMedCrossRef

37.

Duval T, Le Vy S, Stikov N et al (2016) g-Ratio weighted imaging of the human spinal cord in vivo. Neuroimage 145:11–23PubMedCrossRef

38.

Kearney H (2018) Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging—no. Mult Scler. https://doi.org/10.1177/1352458518770279 CrossRefPubMed

39.

Cortese R, Ciccarelli O (2018) Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging—yes. Mult Scler 1:1352458518778010

40.

Fujihara K (2011) Neuromyelitis optica and astrocytic damage in its pathogenesis. J Neurol Sci 306:183–187PubMedCrossRef

41.

Pittock SJ, Lucchinetti CF (2016) Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci 1366:20–39PubMedCrossRef

42.

Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177–189PubMedPubMedCentralCrossRef

43.

Lennon VA, Wingerchuk DM, Kryzer TJ et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112PubMedCrossRef

44.

Lennon VA, Kryzer TJ, Pittock SJ et al (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473–477PubMedPubMedCentralCrossRef

45.

Wingerchuk DM, Lennon VA, Lucchinetti CF et al (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805–815PubMedCrossRef

46.

Papadopoulos MC, Verkman AS (2012) Aquaporin 4 and neuromyelitis optica. Lancet Neurol 11:535–544PubMedPubMedCentralCrossRef

47.

Marignier R, Cobo Calvo A, Vukusic S (2017) Neuromyelitis optica and neuromyelitis optica spectrum disorders. Curr Opin Neurol 30:208–215PubMedCrossRef

48.

Matiello M, Schaefer-Klein J, Sun D et al (2013) Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica. JAMA Neurol 70:1118–1125PubMedCrossRef

49.

Weinshenker BG, Wingerchuk DM, Vukusic S et al (2006) Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 59:566–569PubMedCrossRef

50.

Kitley J, Leite MI, Küker W et al (2013) Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol 70:1375–1381PubMedCrossRef

51.

Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S et al (2015) MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 84:1165–1173PubMedPubMedCentralCrossRef

52.

Takahashi T, Fujihara K, Nakashima I et al (2007) Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 130:1235–1243PubMedCrossRef

53.

Flanagan EP, Weinshenker BG, Krecke KN et al (2015) Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol 72:81–87PubMedPubMedCentralCrossRef

54.

Asgari N, Skejoe HP, Lillevang ST el al (2013) Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study. BMC Neurol 13:33PubMedPubMedCentralCrossRef

55.

Nakamura M, Miyazawa I, Fujihara K et al (2008) Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J Neurol 255:163–170PubMedCrossRef

56.

Kister I, Johnson E, Raz E (2016) Specific MRI findings help distinguish acute transverse myelitis of neuromyelitis optica from spinal cord infarction. Mult Scler Relat Disord 9:62–67PubMedCrossRef

57.

Yonezu T, Ito S, Mori M et al (2014) “Bright spotty lesions” on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis. Mult Scler 20:331–337PubMedCrossRef

58.

Pekcevik Y, Mitchell CH, Mealy MA et al (2016) Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging. Mult Scler 22:302–311PubMedCrossRef

59.

Cassinotto C, Deramond H, Olindo S et al (2009) MRI of the spinal cord in neuromyelitis optica and recurrent longitudinal extensive myelitis. J Neuroradiol 36:199–205PubMedCrossRef

60.

Zalewski NL, Morris PP, Weinshenker BG et al (2017) Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 88:218–225PubMedCrossRef

61.

Zecca C, Disanto G, Sormani MP et al (2016) Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis. Mult Scler 22:782–791PubMedCrossRef

62.

Flanagan EP, Weinshenker BG, Krecke KN et al (2015) Asymptomatic myelitis in neuromyelitis optica and autoimmune aquaporin-4 channelopathy. Neurol Clin Pract 5:175–177PubMedPubMedCentralCrossRef

63.

Liu Y, Wang J, Daams M et al (2015) Differential patterns of spinal cord and brain atrophy in NMO and MS. Neurology 84:1465–1472PubMedCrossRef

64.

Ventura RE, Kister I, Chung S et al (2016) Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions. Neurol Neuroimmunol Neuroinflamm 3:e224PubMedPubMedCentralCrossRef

65.

Sato DK, Callegaro D, Lana-Peixoto MA et al (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82:474–481PubMedPubMedCentralCrossRef

66.

Jitprapaikulsan J, Lopez Chiriboga AS et al (2018) Novel glial targets and recurrent longitudinally extensive transverse myelitis. JAMA Neurol 75:892–895PubMedCrossRefPubMedCentral

67.

Pröbstel AK, Rudolf G, Dornmair K et al (2015) Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflamm 12:46CrossRef

68.

Kitley J, Woodhall M, Waters P et al (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79:1273–1277PubMedCrossRef

69.

Jarius S, Ruprecht K, Kleiter I et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm 13:280CrossRef

70.

Kitley J, Waters P, Woodhall M et al (2014) Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 71:276–283PubMedCrossRef

71.

Wang C, Narayan R, Greenberg B (2018) Anti-myelin oligodendrocyte glycoprotein antibody associated with gray matter predominant transverse myelitis mimicking acute flaccid myelitis: a presentation of two cases. Pediatr Neurol 86:42–45PubMedCrossRef

72.

Narayan R, Simpson A, Fritsche K et al (2018) MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 25:66–72PubMedCrossRef

73.

Bensi C, Marrodan M, González A et al (2018) Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis. Mult Scler Relat Disord 25:246–250PubMedCrossRef

74.

Roelofs RF, Fischer DF, Houtman SH et al (2005) Adult human subventricular, subgranular, and subpial zones contain astrocytes with a specialized intermediate filament cytoskeleton. Glia 52:289–300PubMedCrossRef

75.

Flanagan EP, Hinson SR, Lennon VA et al (2017) Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol 81:298–309PubMedCrossRef

76.

Goh C, Desmond PM, Phal PM (2014) MRI in transverse myelitis. J Magn Reson Imaging 40:1267–1279PubMedCrossRef

77.

Sonneville R, Klein I, de Broucker T et al (2009) Post-infectious encephalitis in adults: diagnosis and management. J Infect 58:321–328PubMedPubMedCentralCrossRef

78.

Pohl D, Alper G, Van Haren K et al (2016) Acute disseminated encephalomyelitis: updates on an inflammatory CNS syndrome. Neurology 87:S38–S45PubMedCrossRef

79.

Callen DJ, Shroff MM, Branson HM et al (2009) Role of MRI in the differentiation of ADEM from MS in children. Neurology 72:968–973PubMedCrossRef

80.

Pröbstel AK, Dornmair K, Bittner R et al (2011) Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 77:580–588PubMedCrossRef

81.

Mealy MA, Wingerchuk DM, Greenberg BM et al (2012) Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol 69:1176–1180PubMed

82.

Sellner J, Hemmer B, Mühlau M (2010) The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes. J Autoimmun 34:371–379PubMedCrossRef

83.

Piga M, Chessa E, Peltz MT et al (2017) Demyelinating syndrome in SLE encompasses different subtypes: do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis. Autoimmun Rev 16:244–252PubMedCrossRef

84.

Saison J, Costedoat-Chalumeau N, Maucort-Boulch D et al (2015) Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients. Lupus 24:74–81PubMedCrossRef

85.

Kovacs B, Lafferty TL, Brent LH et al (2000) Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 59:120–124PubMedPubMedCentralCrossRef

86.

Katramados AM, Rabah R, Adams MD et al (2008) Longitudinal myelitis, aseptic meningitis, and conus medullaris infarction as presenting manifestations of pediatric systemic lupus erythematosus. Lupus 17:332–336PubMedCrossRef

87.

Tono T, Nagai T, Hoshiyama T et al (2016) Transverse myelitis extended to disseminated encephalitis in systemic lupus erythematosus: histological evidence for vasculitis. Mod Rheumatol 26:958–962PubMed

88.

Li XY, Xiao P, Xiao HB et al (2014) Myelitis in systemic lupus erythematosus frequently manifests as longitudinal and sometimes occurs at low disease activity. Lupus 23:1178–1186PubMedCrossRef

89.

Pittock SJ, Lennon VA, de Seze J et al (2008) Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 65:78–83PubMed

90.

Téllez-Zenteno JF, Remes-Troche JM, Negrete-Pulido RO et al (2001) Longitudinal myelitis associated with systemic lupus erythematosus: clinical features and magnetic resonance imaging of six cases. Lupus 10:851–856PubMedCrossRef

91.

Espinosa G, Mendizábal A, Mínguez S et al (2010) Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum 39:246–256PubMedCrossRef

92.

Neumann-Andersen G, Lindgren S (2000) Involvement of the entire spinal cord and medulla oblongata in acute catastrophic-onset transverse myelitis in SLE. Clin Rheumatol 19:156–160PubMedCrossRef

93.

Birnbaum J, Petri M, Thompson R et al (2009) Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum 60:3378–3387PubMedCrossRef

94.

Wingerchuk DM, Lennon VA, Pittock SJ et al (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485–1489PubMedCrossRef

95.

Oiwa H, Kuriyama A, Matsubara T et al (2018) Clinical value of autoantibodies for lupus myelitis and its subtypes: a systematic review. Semin Arthritis Rheum 14:214–220CrossRef

96.

Flanagan EP, McKeon A, Weinshenker BG (2014) Anterior spinal artery infarction causing man-in-the-barrel syndrome. Neurol Clin Pract 4:268–269PubMedPubMedCentralCrossRef

97.

Cervera R, Piette JC, Font J et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027CrossRefPubMed

98.

Sherer Y, Hassin S, Shoenfeld Y et al (2002) Transverse myelitis in patients with antiphospholipid antibodies—the importance of early diagnosis and treatment. Clin Rheumatol 21:207–210PubMedCrossRef

99.

Mori A, Nodera H, Nakane S et al (2010) Transverse myelitis and polymyositis associated with antiphospholipid antibody syndrome. Clin Neurol Neurosurg 112:713–716PubMedCrossRef

100.

Rodrigues CE, de Carvalho JF (2011) Clinical, radiologic, and therapeutic analysis of 14 patients with transverse myelitis associated with antiphospholipid syndrome: report of 4 cases and review of the literature. Semin Arthritis Rheum 40:349–357PubMedCrossRef

101.

Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306PubMedCrossRef

102.

Guerra H, Pittock SJ, Moder KG et al (2018) Frequency of aquaporin-4 immunoglobulin G in longitudinally extensive transverse myelitis with antiphospholipid antibodies. Mayo Clin Proc 93:1299–1304PubMedCrossRef

103.

Greco A, De Virgilio A, Ralli M et al (2018) Behçet’s disease: New insights into pathophysiology, clinical features and treatment options. Autoimmun Rev 17:567–575PubMedCrossRef

104.

Tang Q, Tian J (2016) Longitudinal myelitis of a neuro-Behçet patient. Arch Rheumatol 31:91–93PubMedCrossRef

105.

Mohamed C, Najib K, Essaadouni L (2015) Radiological findings in Behçet disease. Pan Afr Med J 20:51PubMedPubMedCentral

106.

Uygunoglu U, Zeydan B, Ozguler Y et al (2017) Myelopathy in Behçet’s disease: the Bagel sign. Ann Neurol 82:288–298PubMedCrossRef

107.

Borhani Haghighi A, Sarhadi S, Farahangiz S (2011) MRI findings of neuro-Behcet’s disease. Clin Rheumatol 30:765–770PubMedCrossRef

108.

Alexander EL, Provost TT, Stevens MB et al (1982) Neurological complications of primary Sjogren’s syndrome. Medicine (Baltimore) 61:247–257CrossRef

109.

Alexander EL (1986) Central nervous system (CNS) manifestations of primary Sjogren’s syndrome: an overview. Scan J Rheumatol Suppl 61:161–165

110.

Delalande S, de Seze J, Fauchais AL et al (2004) Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 83:280–291CrossRef

111.

Kim SM, Waters P, Vincent A (2009) Sjogren’s syndrome myelopathy: spinal cord involvement in Sjogren’s syndrome might be a manifestation of neuromyelitis optica. Mult Scler 15:1062–1068PubMedCrossRef

112.

Jayarangaiah A, Sehgal R, Epperla N (2014) Sjögren’s syndrome and neuromyelitis optica spectrum disorders (NMOSD)—a case report and review of literature. BMC Neurol 14:200PubMedPubMedCentralCrossRef

113.

Wingerchuk DM, Weinshenker BG (2012) The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler 18:5–10PubMedCrossRef

114.

Stern BJ, Krumholz A, Johns C et al (1985) Sarcoidosis and its neurological manifestations. Arch Neurol 42:909–917PubMedCrossRef

115.

Judson MA, Boan AD, Lackland DT (2012) The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis 29:119–127PubMed

116.

Ricker W, Clark M (1949) Sarcoidosis; a clinicopathologic review of 300 cases, including 22 autopsies. Am J Clin Pathol 19:725–749PubMedCrossRef

117.

Manz HJ (1983) Pathobiology of neurosarcoidosis and clinicopathologic correlation. Can J Neurol Sci 10:50–55PubMedCrossRef

118.

Day AL, Sypert GW (1977) Spinal cord sarcoidosis. Ann Neurol 1:79–85PubMedCrossRef

119.

Durel CA, Marignier R, Maucort-Boulch D et al (2016) Clinical features and prognostic factors of spinal cord sarcoidosis: a multicenter observational study of 20 BIOPSY-PROVEN patients. J Neurol 263:981–990PubMedCrossRef

120.

Sohn M, Culver DA, Judson MA et al (2014) Spinal cord neurosarcoidosis. Am J Med Sci 347:195–198PubMedCrossRef

121.

Flanagan EP (2016) Autoimmune myelopathies. In: Pittock SJ, Vincent A (eds) Handbook of clinical neurology, vol 133. Elsevier, Amsterdam, pp 327–351

122.

Zalewski NL, Krecke KN, Weinshenker BG et al (2016) Central canal enhancement and the trident sign in spinal cord sarcoidosis. Neurology 87:743–744PubMedCrossRef

123.

Jolliffe EA, Keegan BM, Flanagan EP (2018) Trident sign trumps aquaporin-4-IgG ELISA in diagnostic value in a case of longitudinally extensive transverse myelitis. Mult Scler Relat Disord 23:7–8PubMedCrossRef

124.

Kumar N, Frohman EM (2004) Spinal neurosarcoidosis mimicking an idiopathic inflammatory demyelinating syndrome. Arch Neurol 61:586–589PubMedCrossRef

125.

Junger SS, Stern BJ, Levine SR, Sipos E et al (1993) Intramedullary spinal sarcoidosis: clinical and magnetic resonance imaging characteristics. Neurology 43:333–337PubMedCrossRef

126.

Christoforidis GA, Spickler EM, Recio MV et al (1999) MR of CNS sarcoidosis: correlation of imaging features to clinical symptoms and response to treatment. AJNR Am J Neuroradiol 20:655–669PubMedPubMedCentral

127.

Flanagan EP, Keegan BM (2013) Paraneoplastic myelopathy. Neurol Clin 31:307–318PubMedCrossRef

128.

Zalewski NL, Flanagan EP (2018) Autoimmune and paraneoplastic myelopathies. Semin Neurol 38:278–289PubMedCrossRef

129.

Flanagan EP, McKeon A, Lennon VA et al (2011) Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues. Neurology 76:2089–2095PubMedCrossRef

130.

Sepúlveda M, Sola-Valls N, Escudero D et al (2017) Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. Mult Scler. https://doi.org/10.1177/1352458517731914 CrossRefPubMedPubMedCentral

131.

Cai G, He D, Chu L et al (2016) Paraneoplastic neuromyelitis optica spectrum disorders: three new cases and a review of the literature. Int J Neurosci 126:660–668PubMedCrossRef

132.

Ontaneda D, Fox RJ (2014) Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder? Int J Neurosci 124:509–511PubMedCrossRef

Titel: Magnetic resonance imaging in immune-mediated myelopathies
verfasst von: M. J. Wendebourg
S. Nagy
T. Derfuss
K. Parmar
R. Schlaeger
Publikationsdatum: 29.01.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 5/2020
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-019-09206-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Magnetic resonance imaging in immune-mediated myelopathies

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

Single mean arterial blood pressure drops during stroke thrombectomy under general anaesthesia are associated with poor outcome

Correction to: Minimally conscious state “plus”: diagnostic criteria and relation to functional recovery

Reversal of spontaneous nystagmus during visual fixation in dorsal medullary infarction

Gastrointestinal dysfunction in Parkinson’s disease

White matter and cerebellar involvement in alternating hemiplegia of childhood

Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie